Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Phase of Trial: Phase II/III
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Arimoclomol (Primary)
- Indications Inclusion body myositis
- Focus Therapeutic Use
- 24 Oct 2017 This study, if positive, will form the basis for a single study filing for Sporadic Inclusion Body Myositis (IBM). The company expects to complete this trial by the end of 2020.
- 30 Aug 2017 Status changed from not yet recruiting to recruiting.
- 04 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Aug 2017.